These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 34160870)

  • 1. Factor product utilization and health outcomes in patients with haemophilia A and B on extended half-life concentrates: A Canadian observational study of real-world outcomes.
    Sun HL; Yang M; Poon MC; Lee A; Robinson KS; Sholzberg M; Wu J; Iorio A; Blanchette V; Carcao M; Klaassen RJ; Jackson S
    Haemophilia; 2021 Sep; 27(5):751-759. PubMed ID: 34160870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of extended half-life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B.
    Sun HL; Yang M; Poon MC; Lee A; Robinson KS; Sholzberg M; Wu J; Iorio A; Blanchette V; Carcao M; Klaassen RJ; Jackson S
    Res Pract Thromb Haemost; 2021 Oct; 5(7):e12601. PubMed ID: 34667922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgical outcomes in patients with haemophilia A or B receiving extended half-life recombinant factor VIII and IX Fc fusion proteins: Real-world experience in the Nordic countries.
    Lehtinen AE; Baghaei F; Astermark J; Holme PA
    Haemophilia; 2022 Sep; 28(5):713-719. PubMed ID: 35575446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Australian experience with switching to extended half-life factor VIII and IX concentrates: On behalf of the Australian Haemophilia Centre Directors' Organisation.
    Brennan Y; Parikh S; McRae S; Tran H
    Haemophilia; 2020 May; 26(3):529-535. PubMed ID: 32243027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world usage and effectiveness of recombinant factor VIII/factor IX Fc in hemophilia A/B: final data from the 24-month, prospective, noninterventional PREVENT study in Germany.
    Bidlingmaier C; Heller C; Langer F; Miesbach W; Scholz U; Oldenburg J; Nüesch E; Palmborg H; Santagostino E; Tiede A
    Res Pract Thromb Haemost; 2024 Jul; 8(5):102482. PubMed ID: 39101128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching from standard to extended half-life FVIII prophylaxis in haemophilia A: Comparison of factor product use, bleed rates and pharmacokinetics.
    Nummi V; Lehtinen AE; Iorio A; Szanto T; Lassila R
    Haemophilia; 2022 Nov; 28(6):e237-e244. PubMed ID: 35939628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A survey of physicians' treatment switching practice in people on long-term prophylaxis for hemophilia in five European countries.
    van der Sluijs M; Huyghe N; Wood C; Tawil S
    Curr Med Res Opin; 2022 Jan; 38(1):65-73. PubMed ID: 34634979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Effectiveness of rFIXFc Prophylaxis in Patients with Haemophilia B Switched from Standard Half-Life Therapy in Three European Countries.
    Funding E; Lowe G; Poulsen LH; Shapiro S; Oldenburg J; Eriksson D; Falk A; Rich C
    Adv Ther; 2023 Sep; 40(9):3770-3783. PubMed ID: 37351812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world bleeding outcomes and product utilization in people with severe-type hemophilia A before and after switching to extended half-life rFVIIIFc prophylaxis therapy.
    Chang CY; Lai SW; Cheng MM; Ku JT; Hu SH; Liu YL; Tsai JR; Tsai CH; Cheng CN; Chen YC
    Int J Hematol; 2023 Mar; 117(3):378-387. PubMed ID: 36463568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measuring the impact of changing from standard half-life (SHL) to extended half-life (EHL) FVIII prophylaxis on health-related quality of life (HRQoL) in boys with moderate/severe haemophilia A: Lessons learned with the CHO-KLAT tool.
    Carcao M; Zunino L; Young NL; Dover S; Bouskill V; Hilliard P; Price VE; Blanchette VS
    Haemophilia; 2020 Jan; 26(1):73-78. PubMed ID: 31865620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physical activity and bleeding outcomes among people with severe hemophilia on extended half-life or conventional recombinant factors.
    Shrestha A; Su J; Li N; Barnowski C; Jain N; Everson K; Jena AB; Batt K
    Res Pract Thromb Haemost; 2021 Jan; 5(1):94-103. PubMed ID: 33537533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years.
    Shapiro A; Chaudhury A; Wang M; Escobar M; Tsao E; Barnowski C; Feng J; Jain N; Quon DV
    Haemophilia; 2020 Nov; 26(6):975-983. PubMed ID: 33012060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE study.
    Oldenburg J; Hay CRM; Jiménez-Yuste V; Peyvandi F; Schved JF; Szamosi J; Winding B; Lethagen S
    BMJ Open; 2019 May; 9(5):e028012. PubMed ID: 31152037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcomes of prophylaxis with a recombinant factor VIII Fc or recombinant factor IX Fc in patients with hemophilia previously treated on demand.
    Álvarez-Román MT; Shapiro AD; Ragni MV; Palmborg H; Bystrická L; Szamosi J; Casiano S; Chambost H
    Res Pract Thromb Haemost; 2023 Aug; 7(6):102163. PubMed ID: 37720484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indirect comparisons of efficacy and weekly factor consumption during continuous prophylaxis with recombinant factor VIII Fc fusion protein and conventional recombinant factor VIII products.
    Iorio A; Krishnan S; Myrén KJ; Lethagen S; McCormick N; Yermakov S; Karner P
    Haemophilia; 2017 May; 23(3):408-416. PubMed ID: 28233383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia.
    Croteau SE; Cheng D; Cohen AJ; Holmes CE; Malec LM; Silvey M; Thornburg CD; Wheeler AP; Kouides PA; Raffini LJ; Neufeld EJ
    Haemophilia; 2019 Jul; 25(4):668-675. PubMed ID: 30993845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world outcomes with recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis: Longitudinal follow-up in a national adult cohort.
    O'Donovan M; Bergin C; Quinn E; Singleton E; Roche S; Benson J; Bird R; Byrne M; Duggan C; Gilmore R; Ryan K; O'Donnell JS; O'Connell NM
    Haemophilia; 2021 Jul; 27(4):618-625. PubMed ID: 33939224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world evidence on efmoroctocog alfa in patients with haemophilia A: A systematic literature review of treatment experience in Europe.
    Blatný J; Nielsen EM; Reitzel SB; McMillan AC; Danø A; Bystrická L; Kragh N; Klamroth R
    Haemophilia; 2023 Jul; 29(4):963-974. PubMed ID: 37243934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States.
    Aledort L; Milligan S; Watt M; Booth J
    J Manag Care Spec Pharm; 2020 Apr; 26(4):492-503. PubMed ID: 32223610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes of low-dose pharmacokinetic-guided extended half-life versus low-dose standard half-life factor VIII concentrate prophylaxis in haemophilia A patients.
    Rakmanotham A; Moonla C; Sosothikul D
    Haemophilia; 2023 Jan; 29(1):156-164. PubMed ID: 36409282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.